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Table IV:  Guidelines for Age-Appropriate Cancer Screening* 735 
Malignancy Age Screen Frequency 
Level of 
Evidence 
Breast cancer96 50 to 74 Mammogram Every 2 years IA 
Cervical cancer97 21 to 65 Pap smear Every 3 years IB 
Colon cancer98 50 to 75 
Fecal occult blood test 
(FOBT) 
Yearly 
IB Flexible sigmoidoscopy + 
FOBT 
Every 5 years 
(flexible 
sigmoidoscopy) 
Every 3 years 
(FOBT) 
Colonoscopy Every 10 years 
Lung cancer99 
55 to 80 with ≥30 
pack-year history 
and current 
smoker or quit 
within 15 years 
Low dose computed 
tomography of the chest 
Yearly 
 
IA 
 
 736 
*Refer to guideline reference documents for full screening recommendations. 737 
44 
 
Level of evidence definitions:  IA, evidence from meta-analysis of randomized controlled trials; 738 
IB, evidence from at least one randomized controlled trial; IIA, evidence from at least one 739 
controlled study without randomization; IIB, evidence from at least one other type of 740 
experimental study; III, evidence from nonexperimental descriptive studies, such as comparative 741 
studies, correlation studies, and case-control studies; IV, evidence from expert committee reports 742 
or opinions or clinical experience of respected authorities, or both.  743 
